Premium
Pharmacological treatment for Type 2 diabetes integrating findings from cardiovascular outcome trials: an expert consensus in the UK
Author(s) -
Bain S. C.,
Bakhai A.,
Evans M.,
Green A.,
Menown I.,
Strain W. D.
Publication year - 2019
Publication title -
diabetic medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.474
H-Index - 145
eISSN - 1464-5491
pISSN - 0742-3071
DOI - 10.1111/dme.14058
Subject(s) - medicine , nice , type 2 diabetes , intensive care medicine , excellence , diabetes mellitus , disease , clinical trial , endocrinology , law , political science , computer science , programming language
In people with Type 2 diabetes, cardiovascular disease is a leading cause of morbidity and mortality. Thus, as well as controlling glucose, reducing the risk of cardiovascular events is a key goal. The results of cardiovascular outcome trials have led to updates for many national and international guidelines. England, Wales and Northern Ireland remain exceptions, with the most recent update to the National Institute for Health and Care Excellence ( NICE ) guidelines published in 2015. We reviewed current national and international guidelines and recommendations on the management of people with Type 2 diabetes. This article shares our consensus on clinical recommendations for the use of sodium‐glucose co‐transporter 2 inhibitors ( SGLT ‐2is) and glucagon‐like peptide 1 receptor agonists ( GLP ‐1 RA s) in people with Type 2 diabetes and established or at very high risk of cardiovascular disease in the UK . We also consider cost‐effectiveness for these therapies. We recommend considering each person's cardiovascular risk and using diabetes therapies with proven cardiovascular benefits when appropriate to improve long‐term outcomes and cost‐effectiveness.